Valuation BlossomHill Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 13/11/2026 GMT			5-day change	1st Jan Change
14.02 ^USD	-5.53%		+3.85%	-

11-12	BlossomHill Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-09	BlossomHill Therapeutics to Advance BH-30643 to Phase 2 After FDA Alignment on Dosage	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2026	2027	2028
Market Cap ¹	445.6	-	-
Change	-	-	-
Enterprise Value (EV)	445.6	445.6	445.6
Change	-	0%	0%
P/E	-2.47x	-4.3x	-4.07x
PBR	-	-	-
PEG	-0.36x	0.1x	-0.73x
Capitalization / Revenue	-	-	-
EV / Revenue	-	-	-
EV / EBITDA	-4x	-3.28x	-2.8x
EV / EBIT	-4.06x	-3.43x	-2.76x
EV / FCF	-4.84x	-3.94x	-4.67x
FCF Yield	-20.6%	-25.4%	-21.4%
Dividend per Share ²	-	-	-
Rate of return	-	-	-
EPS ²	-5.667	-3.26	-3.441
Distribution rate	-	-	-
Net sales ¹	-	-	-
EBITDA ¹	-111.5	-135.7	-159.4
EBIT ¹	-109.7	-130.1	-161.5
Net income ¹	-102.6	-118.9	-149.7
Net Debt	-	-	-
Reference price ²	14.02	14.02	14.02
Nbr of stocks (in thousands)	31,785	-	-
Announcement Date	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	-2.47x	-	-	-	446M
WUXI APPTEC CO., LTD.	17.35x	6.64x	12.72x	1.72%	66.33B
ARGENX SE	32.78x	8.77x	28.98x	0.07%	60.62B
LONZA GROUP AG	38.6x	6.87x	20.53x	0.84%	55.5B
BEONE MEDICINES AG	44.7x	6.26x	29.77x	-.--%	47.58B
IQVIA HOLDINGS INC.	34.6x	3.29x	14.2x	-.--%	43.69B
REVOLUTION MEDICINES, INC.	-20.57x	54.42x	-22.49x	-.--%	37.27B
CELLTRION, INC.	36.15x	8.94x	23.31x	0.36%	36.57B
GENMAB A/S	40.59x	7.89x	26.33x	-.--%	32.22B
INSMED INCORPORATED	-73.93x	14x	-75.29x	-.--%	26.58B
Average	14.78x	13.01x	6.45x	0.33%	41B
Weighted average by Cap.	21.67x	11.75x	11.42x	0.44%